ADAMTS13 Activity with Reflex to Inhibitor

If the vWF Protease Activity result is < or = 40, vWF Protease Inhibitor will be performed at an additional charge (CPT: 85335).

SRHC Clients:

Outpatients:  Send patient to SRHC laboratory for collection due to processing and stability requirements

Inpatients:
 

• 1 light blue top tube (3.2% Sodium Citrate)
• Must be processed for platelet poor plasma and frozen within 1 hour of collection
• Send to SRHC laboratory immediately for processing

 

 

LAB70003

145328

ADAMTS
ADAMTS-13

If the ADAMTS13 Activity result is ≤0.30 IU/mL, then ADAMTS13 Inhibitor will be performed at an additional charge (CPT: 85335).

1 mL frozen plasma collected in a 3.2% sodium citrate (light blue-top) tube

0.5 mL

Please submit a separate, frozen vial for each special coagulation assay ordered. Draw blood in a light blue-top tube containing 3.2% sodium citrate, mix gently by inverting 3-4 times. Centrifuge 15 minutes at 1500 g within one hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Freeze immediately and transport on dry ice.

Transport tube

Frozen

Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 21 days

Gross hemolysis • Grossly lipemic • Grossly icteric

Set up: Sun-Fri; Report available: 2-4 days

ADAMTS-13 is a zinc metalloprotease that cleaves ultra large vWF multimers. Studies have shown that low levels of ADAMTS-13 activity are associated with thrombotic thrombocytopenic purpura (TTP), a life-threatening hematological condition characterized by a low platelet count, microvascular thrombi, red cell fragmentation, and renal complications. Congenital TTP is a rare inherited disease caused by mutations within the ADAMTS-13 gene, which result in the production of non-functional protein. The acquired form of TTP is an autoimmune-like disorder caused by the development of autoantibodies to ADAMTS-13 that inhibits enzyme activity.